WORCESTER, Mass., May 15, 2009 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has consummated a registered direct offering of 15,151,517 shares of its common stock to a select group of accredited investors at $0.33 per share. The offering resulted in net proceeds of approximately $4.8 million, after deducting the placement agent's fees and estimated offering expenses. Rodman & Renshaw, LLC, a subsidiary of Rodman & Renshaw Capital Group, Inc., (Nasdaq:RODM), acted as the exclusive placement agent for the transaction.
